Home › Compare › PGLDF vs ABBV
PGLDF yields 413.22% · ABBV yields 3.06%● Live data
📍 PGLDF pulled ahead of the other in Year 1
Combined, PGLDF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PGLDF + ABBV for your $10,000?
P2 Gold Inc., a junior mining company, engages in the acquisition, exploration, and development of mineral properties in Canada and the United States. It primarily explores for gold, copper, silver, lead, and zinc deposits. The company holds an interest in the Gabbs project comprising 421 unpatented lode mining claims and one patented lode mining claim covering 3,300 hectares in Nevada; the Silver Reef project covering an area of approximately 23,000 hectares; and the BAM property, which includes ten mineral tenures that covers an area of approximately 8,100 hectares. It also holds an interest in the Lost Cabin property comprising 106 unpatented lode mining claims covering an area of approximately 2,190 acres, located in Lake County, Oregon. The company was formerly known as Central Timmins Exploration Corp. and changed its name to P2 Gold Inc. in August 2020. P2 Gold Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Full PGLDF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.